Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 9c

Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.07, $0.09 better than the analyst estimate of ($0.02). Loss from continuing ops was ($0.03). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $8.02 million.

Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)